Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Doskaliuk (Ivano-Frankivsk, Ukraine), L. Zaiats (Ivano-Frankivsk, Ukraine), R. Yatsyshyn (Ivano-Frankivsk, Ukraine). Alveolar–capillary barrier alteration due to systemic sclerosis: an experimental study.. 3607

Member's Comments

No comment yet.

Related content which might interest you: Experimental modeling of lung involvement due to systemic sclerosis. Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Clinical feature of systemic sclerosis associated with pulmonary hypertension: results of one center study Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Membrane diffusion and capillary blood volume in systemic sclerosis-associated pulmonary arterial hypertension (SScPAH) and systemic sclerosis (SSc) without PAH Source: Eur Respir J 2007; 30: Suppl. 51, 342s Year: 2007 Pulmonary hypertension in systemic sclerosis: different phenotypes Source: Eur Respir Rev, 26 (145) 170056; 10.1183/16000617.0056-2017 Year: 2017 Arterial type V collagen disorganization in patients with systemic sclerosis: preliminary study Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Pulmonary interstitium remodeling by collagen V is associated with profibrotic cytocines in experimental systemic sclerosis Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Collagen V nasal tolerance promotes decrease in topoisomerase-1 and pulmonary fibrosis of systemic sclerosis model Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Pulmonary involvement in systemic sclerosis Source: Eur Respir Monogr 2019; 86: 90-105 Year: 2019 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Pulmonary arterial hypertension in systemic sclerosis: a distinctive endotheliopathy? Source: Eur Respir J 2010; 35: 223-224 Year: 2010 Pulmonary function in progressive systemic sclerosis Source: Eur Respir J 2002; 20: Suppl. 38, 62s Year: 2002 Pulmonary functions in systemic sclerosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Gas transfer measurement in systemic sclerosis associated pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 543s Year: 2005 Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Metabolic profiling of pulmonary vascular phenotypes in systemic sclerosis Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 Interstitial lung disease in systemic sclerosis: where do we stand? Source: Eur Respir Rev 2015; 24: 411-419 Year: 2015 Pulmonary fibrosis is associated with emphysema in systemic sclerosis: indirect support for a smoking pathogenesis hypothesis Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009